ERBB2 and breast cancer: Although estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) are currently used in the clinic for prognostic evaluation as well as to assort breast cancer patients for appropriately targeted therapies, treatment failure often occurs in triple-negative breast cancer (TNBC) that accounts for approximately 15–20% of breast cancer patients [8].